Results 11 to 20 of about 696,028 (214)

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Alzheimer’s Research & Therapy, 2022
Background The need for preventive therapies that interrupt the progression of Alzheimer’s disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and has spurred the ongoing development of disease-modifying therapies (DMTs) in ...
Sheila Seleri Assunção, Reisa A. Sperling, Craig Ritchie, Diana R. Kerwin, Paul S. Aisen, Claire Lansdall, Alireza Atri, Jeffrey Cummings   +7 more
doaj   +1 more source

Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases

BMC Health Services Research, 2016
Background Previous evaluations of oncological medicines in the German early benefit assessment (EBA) procedure have demonstrated inconsistent acceptance of endpoints by regulatory authorities and the Federal Joint Committee (G-BA).
Thomas Staab, Georg Isbary, Volker E. Amelung, Jörg Ruof   +3 more
doaj   +1 more source

Clinical relevance of sentinel lymph node biopsy in early ovarian cancer [PDF]

Obstetrics & Gynecology Science, 2023
The first-line treatment for early ovarian cancer typically involves primary debulking surgery aimed at maximal cytoreduction, alongside adjuvant chemotherapy if clinically indicated.
Ki Eun Seon, Sang Wun Kim, Young Tae Kim
doaj   +1 more source

“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations

Health Economics Review, 2018
Background According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of new medicines as a basis for subsequent price negotiations.
Thomas R. Staab, Miriam Walter, Sonja Mariotti Nesurini, Charalabos-Markos Dintsios, J.-Matthias Graf von der Schulenburg, Volker E. Amelung, Jörg Ruof   +6 more
doaj   +1 more source

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree

Health Economics Review, 2019
Background The purpose of this study was to analyse the impact of commissioned addenda by the Federal Joint Committee (FJC) to the HTA body (IQWiG) and their agreement with FJC decisions and to identify potential additional decisive factors of FJC ...
C. M. Dintsios, F. Worm, J. Ruof, M. Herpers   +3 more
doaj   +1 more source

Qualitative assessment of innovations in healthcare provision

BMC Health Services Research, 2009
Background The triad of quality, innovation and economic restraint is as important in health care as it is in the business world. There are many proposals for the assessment of quality and of economic restraints in health care but only a few address ...
Ghosh Amit K, Porzsolt Franz, Kaplan Robert M   +2 more
doaj   +1 more source

Quantitative Benefit–Risk Assessment of COVID-19 Vaccines Using the Multi-Criteria Decision Analysis

Vaccines, 2022
In the early SARS-CoV-2 (COVID-19) pandemic, four major vaccines were approved despite limited efficacy and safety data through short regulatory review periods. Thus, it is necessary to assess the benefit-risk (BR) profiles of the COVID-19 vaccines.
Kyung-Hwa Son, Sun-Hong Kwon, Hye-Jung Na, Youngsuk Baek, Inok Kim, Eui-Kyung Lee   +5 more
doaj   +1 more source

Concept and application of the probability of pharmacological success (PoPS) as a decision tool in drug development: a position paper

Journal of Translational Medicine, 2023
Background In drug development, few molecules from a large pool of early candidates become successful medicines after demonstrating a favourable benefit-risk ratio.
Chao Chen, Xuan Zhou, Silvia Maria Lavezzi, Usman Arshad, Raman Sharma   +4 more
doaj   +1 more source

The Role of Thrombelastography in Multiple Trauma

Emergency Medicine International, 2011
Hemorrhage and traumatic coagulopathyis are major causes of early death in multiply injured patients. Thrombelastography (TEG) seems to be a fast and accurate coagulation test in trauma care. We suggest that multiply injured trauma patients would benefit
Victor Jeger, Heinz Zimmermann, Aristomenis K. Exadaktylos   +2 more
doaj   +1 more source

The impact of early comprehensive geriatric screening on the readmission rate in an acute geriatric ward: a quasi-experimental study

BMC Geriatrics, 2019
Background Unplanned readmission is an important healthcare quality issue. We studied the effect of a comprehensive geriatric screen (CGS) in the early admission course followed by a comprehensive geriatric assessment on readmission rates in elderly ...
Kun-Pei Lin, Jen-Hau Chen, Feng-Ping Lu, Chiung-Jung Wen, Ding-Cheng (Derrick) Chan   +4 more
doaj   +1 more source